S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
'Civil War’ continues box-office campaign at No. 1
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
'Civil War’ continues box-office campaign at No. 1
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
'Civil War’ continues box-office campaign at No. 1
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
'Civil War’ continues box-office campaign at No. 1
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Tens of thousands of Colombians protest against the leftist president's reform agenda

HUTCHMED (HCM) Competitors

$16.50
+0.14 (+0.86%)
(As of 04/19/2024 ET)

HCM vs. ARWR, ACAD, MLTX, IDYA, MOR, FOLD, XENE, INDV, BHC, and JANX

Should you be buying HUTCHMED stock or one of its competitors? The main competitors of HUTCHMED include Arrowhead Pharmaceuticals (ARWR), ACADIA Pharmaceuticals (ACAD), MoonLake Immunotherapeutics (MLTX), IDEAYA Biosciences (IDYA), MorphoSys (MOR), Amicus Therapeutics (FOLD), Xenon Pharmaceuticals (XENE), Indivior (INDV), Bausch Health Companies (BHC), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical preparations" industry.

HUTCHMED vs.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and HUTCHMED (NASDAQ:HCM) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, community ranking, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 8.8% of HUTCHMED shares are held by institutional investors. 4.5% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 3.6% of HUTCHMED shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Arrowhead Pharmaceuticals had 1 more articles in the media than HUTCHMED. MarketBeat recorded 3 mentions for Arrowhead Pharmaceuticals and 2 mentions for HUTCHMED. Arrowhead Pharmaceuticals' average media sentiment score of 0.84 beat HUTCHMED's score of 0.60 indicating that HUTCHMED is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arrowhead Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
HUTCHMED
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Arrowhead Pharmaceuticals received 209 more outperform votes than HUTCHMED when rated by MarketBeat users. However, 66.74% of users gave HUTCHMED an outperform vote while only 65.25% of users gave Arrowhead Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Arrowhead PharmaceuticalsOutperform Votes
522
65.25%
Underperform Votes
278
34.75%
HUTCHMEDOutperform Votes
313
66.74%
Underperform Votes
156
33.26%

HUTCHMED has a net margin of 0.00% compared to HUTCHMED's net margin of -163.32%. Arrowhead Pharmaceuticals' return on equity of 0.00% beat HUTCHMED's return on equity.

Company Net Margins Return on Equity Return on Assets
Arrowhead Pharmaceuticals-163.32% -90.77% -38.56%
HUTCHMED N/A N/A N/A

Arrowhead Pharmaceuticals has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500.

HUTCHMED has higher revenue and earnings than Arrowhead Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arrowhead Pharmaceuticals$240.74M11.49-$205.27M-$2.78-8.03
HUTCHMED$838M3.43$100.78MN/AN/A

Arrowhead Pharmaceuticals currently has a consensus target price of $53.45, suggesting a potential upside of 139.38%. HUTCHMED has a consensus target price of $29.70, suggesting a potential upside of 80.00%. Given HUTCHMED's higher probable upside, equities analysts clearly believe Arrowhead Pharmaceuticals is more favorable than HUTCHMED.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arrowhead Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.67
HUTCHMED
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

Summary

HUTCHMED beats Arrowhead Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HCM vs. The Competition

MetricHUTCHMEDPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.88B$6.42B$4.88B$7.32B
Dividend YieldN/A3.10%2.92%3.97%
P/E RatioN/A9.04179.4516.66
Price / Sales3.43307.642,464.8581.89
Price / Cash26.3828.9747.3834.38
Price / Book3.865.324.564.15
Net Income$100.78M$140.57M$104.42M$214.00M
7 Day Performance-7.72%-6.71%-4.52%-3.51%
1 Month Performance-4.46%-9.68%-6.81%-6.05%
1 Year Performance0.92%-6.66%6.58%3.98%

HUTCHMED Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARWR
Arrowhead Pharmaceuticals
3.8591 of 5 stars
$23.67
-1.4%
$53.45
+125.8%
-25.4%$2.93B$240.74M-8.51525Positive News
ACAD
ACADIA Pharmaceuticals
3.5245 of 5 stars
$17.08
+1.1%
$35.82
+109.7%
-15.8%$2.81B$726.44M-44.95597Short Interest ↑
MLTX
MoonLake Immunotherapeutics
2.1969 of 5 stars
$43.50
-0.3%
$74.46
+71.2%
+98.2%$2.78BN/A-57.2450Positive News
IDYA
IDEAYA Biosciences
3.4899 of 5 stars
$41.17
-0.8%
$44.55
+8.2%
+155.0%$3.07B$23.39M-20.90124Short Interest ↑
News Coverage
MOR
MorphoSys
0.6819 of 5 stars
$17.95
-0.4%
$11.78
-34.4%
+257.5%$2.70B$257.89M-11.51524
FOLD
Amicus Therapeutics
3.3157 of 5 stars
$10.56
-0.9%
$20.00
+89.4%
-7.7%$3.12B$399.36M-20.71517Positive News
XENE
Xenon Pharmaceuticals
1.8441 of 5 stars
$41.49
+0.4%
$59.44
+43.3%
+4.4%$3.13B$9.43M-15.25251Options Volume
INDV
Indivior
3.1708 of 5 stars
$19.39
-1.8%
$36.00
+85.7%
N/A$2.67B$1.09B-969.021,164Upcoming Earnings
BHC
Bausch Health Companies
4.0094 of 5 stars
$8.74
+1.3%
$13.00
+48.7%
+13.0%$3.19B$8.76B-5.4020,270Short Interest ↓
JANX
Janux Therapeutics
2.6293 of 5 stars
$50.55
-2.5%
$61.33
+21.3%
+210.1%$2.61B$8.08M-37.7264Analyst Report

Related Companies and Tools

This page (NASDAQ:HCM) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners